🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for MSS Metastatic Colorectal Cancers

Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status. NCT07595276Phase 31 site📍 Guangzhou Taizhou Mabtech Pharmaceutical Co.,Ltd · Tests: Enlituo®, Erbitux® FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver Metastasis NCT06801665Phase 21 site📍 Changzhou Hua Jiang · Tests: FMT+QL1706+Bevacizumab+XELOX New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer NCT07559760Phase 21 site📍 Changchun The First Hospital of Jilin University · Tests: Levofolinic Acid + 5-FU continuous infusion + irinotecan HCl liposome ± cetuximab/bevacizumab A Study of ASP1002 in Adults for Treatment of Solid Tumors NCT05719558Phase 115 sites📍 New Haven📍 Plainville📍 Gainesville Astellas Pharma Global Development, Inc. · Tests: ASP1002, Bevacizumab, Oxaliplatin, Leucovorin, Fluorouracil Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer NCT06522919Phase 22 sites📍 Meldola📍 Tricase Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IR… · Tests: Autologous Dendritic Cell (DC) Vaccine Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer NCT07718490Phase 22 sites📍 Nanjing📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Adebrelimab Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC NCT07281716Phase 1, Phase 21 site📍 New York Dan Feng · Tests: Nadunolimab, Toripalimab KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer NCT05985109Phase 21 site📍 Beijing Peking University Cancer Hospital & Institute · Tests: KN046, regorafenib A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer NCT07321106Phase 110 sites📍 Phoenix📍 Duarte📍 Los Angeles Cartography Biosciences · Tests: CBI-1214 A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer NCT06979908Phase 21 site📍 Changchun The First Hospital of Jilin University · Tests: Fruquintinib+Sintilimab+Chidamide Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer NCT06176885Phase 21 site📍 Jinhua yue junhan · Tests: Camrelizumab A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer NCT07079631Phase 1, Phase 214 sites📍 New Haven📍 Grand Rapids📍 Cleveland BioNTech SE · Tests: BNT314, Pumitamig, SoC chemotherapy treatment 1, SoC chemotherapy treatment 2, Bevacizumab Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer NCT05959356Phase 23 sites📍 Foshan📍 Guangzhou📍 Guiyang Sun Yat-sen University · Tests: Cetuximab + Envafolimab + mFOLFOXIRI, Cetuximab + mFOLFOX6 Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC NCT06551207NA1 site📍 Wuhan Liu Huang · Tests: Fruquintinib, Cadonilimab, SBRT Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer. NCT06613113NA1 site📍 Ningbo Ningbo Medical Center Lihuili Hospital · Tests: Fruquintinib - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases NCT06856837Phase 223 sites📍 Linz📍 Salzburg📍 Wiener Neustadt Institut für Klinische Krebsforschung IKF GmbH at Krankenha… · Tests: Fruquintinib, Tislelizumab, Trifluridine/tipiracil, Bevacizumab FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer NCT07446322Phase 219 sites📍 Homewood📍 Beverly Hills📍 Encino Oncolytics Biotech · Tests: Bevacizumab, FOLFIRI, Pelareorep A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer NCT07506109Phase 24 sites📍 Beijing📍 Wuhan📍 Chengdu Tianjin Medical University Cancer Institute and Hospital · Tests: Ipilimumab N01, Sintilimab, Cetuximab, Dabrafenib FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. NCT06733038Phase 324 sites📍 Brescia📍 Catania📍 Meldola Gruppo Oncologico del Nord-Ovest · Tests: Atezolizumab, Bevacizumab, Irinotecan (CPT-11), Oxaliplatin, Leucovorin Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer NCT06566755Phase 31 site📍 Shenyang Caigang Liu · Tests: Cadonilimab (AK104) combined with chemotherapy and bevacizumab A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy NCT06549907n/a1 site📍 Beijing Peking University Cancer Hospital & Institute · Tests: Multi-omics testing, MRI ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC NCT06321081Phase 21 site📍 Beijing Beijing Hospital · Tests: irinotecan, cetuximab, envafolimab Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC NCT05768503Phase 312 sites📍 Hefei📍 Foshan📍 Guangzhou Sun Yat-sen University · Tests: Experimental drug, Control Rx GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC. NCT06558773Phase 21 site📍 Beijing Chinese PLA General Hospital · Tests: Regorafenib+Immune checkpoint inhibitor, Eliglustat+Immune checkpoint inhibitor, Eliglustat+Immune checkpoint inhibitor… Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma NCT06484153Phase 21 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: Pirfenidone, Fruquintinib, Pembrolizumab Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer NCT06218810Phase 21 site📍 Shanghai Fudan University · Tests: Cadonilimab + bevacizumab + FOLFOX Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS) NCT06634875Phase 23 sites📍 Los Angeles📍 Newport Beach📍 Atlanta Buzzard Pharmaceuticals · Tests: isunakinra PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer NCT07133750Phase 211 sites📍 Beijing📍 Guangzhou📍 Guangzhou Biotheus Inc. · Tests: PM8002, Chemotherapy Regimen 1, Chemotherapy Regimen 2, Chemotherapy Regimen 3 Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases NCT07277322Phase 1, Phase 21 site📍 New York Dan Feng · Tests: Dupilumab, Toripalimab FOG-001 in Locally Advanced or Metastatic Solid Tumors NCT05919264Phase 1, Phase 233 sites📍 Phoenix📍 Scottsdale📍 Tucson Parabilis Medicines, Inc. · Tests: FOG-001, mFOLFOX-6, Nivolumab, Trifluridine/tipiracil, Bevacizumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy